Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07246967
Recruiting Not applicable

Antibiotic Prophylaxis for Ureteroscopy With a Negative Pressure Suction Sheath

NCT07246967 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase
Not applicable
Started
2026-02-01
Last updated
2026-04-23

Condition(s) studied

UrolithiasisAntibiotics

Investigational drug(s) / intervention(s)

not use any prophylactic antimicrobialsuse prophylactic antimicrobials

not use any prophylactic antimicrobials: The experimental group will undergo surgery without the use of any prophylactic antimicrobials; therapeutic antimicrobials will only be administered postoperatively to patients who develop signs or symptoms of infection. The control group will receive a single dose of intravenous prophylactic antimicrobials 30-60 minutes before surgery, followed by the same standardized surgical procedure.

use prophylactic antimicrobials: Receive a single dose of intravenous prophylactic antimicrobials (e.g., a second-generation cephalosporin or levofloxacin) 30-60 minutes before surgery, followed by the same standardized flexible negative-pressure sheath ureteroscopic surgery.

Study summary

This study, as a prospective, randomized, controlled, non-inferiority, international multicenter clinical trial, aims to evaluate whether a strategy of no antimicrobial prophylaxis is non-inferior to the traditional single-dose prophylaxis regimen in patients with a low risk of infection undergoing single-use flexible ureteroscopic lithotripsy combined with a flexible negative-pressure suction sheath. It is anticipated that this will have a substantial impact on infection prevention strategies in urological surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age 18-75 years. 2. Diagnosed by CT with renal and/or upper ureteral stones, with the longest stone diameter being ≤2cm. 3. Scheduled to undergo fURS lithotripsy. 4. No preoperative symptoms of infection such as chills and fever, and the most recent preoperative urine culture is negative. 5. No immunosuppressive status and no urinary flow obstruction caused by anatomical abnormalities. 6. No use of long-acting antimicrobial agents within 7 days prior to surgery, and no use of intermediate or short-acting antimicrobial agents within 72 hours prior to surgery. 7. Has signed and dated an informed consent form, indicating that the patient or their legal representative has been fully informed about the study-related information and has agreed to participate. Exclusion Criteria: 1. Pregnant or lactating women. 2. Allergy to the investigational drug(s). 3. Participation in other clinical trials within 30 days. 4. Presence of other active infection foci requiring antimicrobial treatment. 5. Concomitant severe systemic diseases, such as cardiac or pulmonary disease, malignant tumors, and immunodeficiency states. 6. Congenital malformations of the urinary tract. 7. History of kidney transplantation or urinary diversion surgery. 8. Unable to provide samples or complete follow-up according to the study protocol. 9. Unable to provide informed consent. 10. Inability to achieve complete placement of the flexible negative-pressure suction sheath. 11. Any other conditions that the investigator deems unsuitable for participation in this study. 12. History of diabetes mellitus, immunocompromised. 13. Renal insufficiency, neurogenic bladder. 14. Recent preoperative history of stone-related fever. 15. Long-term indwelling urinary drainage tube. 16. Urine white blood cells \>5/HPF (High Power Field) or positive for urine nitrites. 17. Large stone burden (e.g., staghorn calculus) or moderate to severe hydronephrosis. 18. Imaging findings showing turbid urine in the renal pelvis where pyonephrosis or infectious stones cannot be excluded.

Primary outcome measure(s)

  • the incidence of Systemic Inflammatory Response Syndrome (SIRS) within 72 hours postoperatively — within 72 hours postoperatively
    To reduce the influence of subjective factors and to more comprehensively reflect the systemic inflammatory state, the primary endpoint is the incidence of Systemic Inflammatory Response Syndrome (SIRS) within 72 hours postoperatively, defined as meeting at least two of the following criteria: Body temperature \>38°C or \<36°C Heart rate \>90 beats/minute Respiratory rate \>20 breaths/minute or PaCO2 \<32 mmHg White blood cell count \>12×10⁹/L or \<4×10⁹/L, or \>10% immature neutrophils

Trial sites (1)

FacilityCityRegionStatus
Shanghai General Hospital Shanghai Shanghai Municipality Recruiting

More Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine trials in China

Efficacy of S.T.O.P®KIT in Retarding Axial Length Growth in Children With Low Hyperopia Starting soon
Application of Quantitative Hemorrhage Detection in Fetomaternal Hemorrhage Syndrome for the Diagnosis of Hemolytic Disease of the Newborn Starting soon
PSMA-PET/MRI-Ultrasound Multimodal Fusion Navigation for Da Vinci Robot-Assisted Radical Prostatectomy: A Randomized Controlled Trial Starting soon
Prognostic Study of Via Dynamic Change of dT-DNA in Drainage Fluid After Radical Prostatectomy Starting soon
Multicenter RCT: LED Red Light Dose-Response in Myopia Progression Control Starting soon

Other trials for the same condition

Comparison of Stent-Related Symptoms Between Anti-Reflux Stents and Standard DJ Stents in Children With Urolithiasis Recruiting
Predictive Value of Preoperative Urine Culture for Postoperative Fever After FANS-RIRS When Surgery Proceeds Before Culture Results Are Available Active, not recruiting
A Study on the Application of NE Irrigation Fluid for Hemostasis in Flexible Ureteroscopic Lithotripsy: A Prospective Single-arm Interventional Study of Upper Urinary Tract Calculi.(NE: Norepinephrine) Recruiting
Analysis of the Effectiveness and Safety of RIRS Under Local Anesthesia and Its Influencing Factors Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07246967 on ClinicalTrials.gov ↗ ← All trials in China